Genmab's blockbuster Darzalex surpasses $2B in sales

Genmab A/S (CSE:GEN; Pink:GMXAY) said sales of its multiple myeloma drug Darzalex daratumumab reached $2 billion in 2018, triggering a

Read the full 206 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE